VTCN1 and cancer: Table 3 shows the presence of the respective ICs in the entire study group, as well as individually in the subgroups of survivors and non-survivors. VISTA and PD-L1 were present in cancer cells of 30.9% (n = 17), and 38.2% (n = 21) of the resected tumors in the subgroup of non-survivors and only in 7.7% (n = 1) and 15.4% (n = 2) of tumors in the subgroup of survivors, respectively. Representative examples of presence and absence of TIM3, IDO, B7H4, LAG3, VISTA and PD-L1 in immunohistochemical (IHC) staining are presented in Figure 1A–L.